ネダプラチン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

• 注意書き

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

ネダプラチン 価格

ネダプラチン 化学特性,用途語,生産方法

• 溶解性

  水に溶ける。

• 用途

  DNA 鎖内及び鎖間で DNA 架 橋を形成し、DNA の複製及び転写阻害作用を 示します。

• 効能

  抗悪性腫瘍薬, 細胞増殖阻害薬

• 商品名

  アクプラ (日医工)

• 説明

  Nedaplatin, a novel second generation platinum complex, was marketed in Japan for the treatment of a variety of cancers including: head and neck, small-cell and non-small cell lung, oesophageal, prostatic, testicular, ovarian, cervical, bladder, and uterine cancers. Platinum anticancer agents, prototyped by cisplatin, have been reported to be hydrolyzed to the mono- or diaquated species of diamine platinum which react with nucleophilic sites on DNA to cause intrastrand and interstrand crosslinks and DNA-protein crosslinks, which result in cytotoxicity. Nedaplatin was reportedly more active than cisplatin against several solid tumors while sharing less nephro- and gastrointestinal toxicity to cisplatin in viva The minimal renal toxicity displayed by nedaplatin allows its use in patients with deteriorated renal function.

• 使用

  Nedaplatin is a platinum complex that has potent antineoplatic activity.

• 応用例（製薬）

  Nedaplatin, cis-diammineglycolatoplatinum(II), is structurally similar to carboplatin. The chemical structure consists of a central platinum(II) atom with two cis-ammonia groups as nonleaving groups and – in contrast to carboplatin – the dianionic form of glycolic acid as the leaving group. Nedaplatin has been approved for the clinical use in the Japanese market for the treatment of head and neck, testicular, ovarian, lung and cervical cancer. It is typically administered by IV injection and its dose-limiting side effect is myelosuppression.

ネダプラチン 生産企業

Global(217)Suppliers

ネダプラチン スペクトルデータ(¹HNMR)

95734-82-0, ネダプラチン キーワード